^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TXA-127

    i
    Other names: TXA-127, TXA127, angiotensin 1-7
    Associations

    News

    Trials
    Company:
    Constant Therap
    Drug class:
    MAS1 agonist
    Associations

    News

    Trials
    almost2years
    NECTAR: Novel Experimental COVID-19 Therapies Affecting Host Response (clinicaltrials.gov)
    P2/3, N=871, Completed, Sean Collins | Active, not recruiting --> Completed
    Trial completion
    |
    Tavalisse (fostamatinib) • TXA-127
    2years
    Phase 2 Study of TXA127 in Post-ischemic Stroke Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, Constant Therapeutics LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BDNF (Brain Derived Neurotrophic Factor) • NEFL (Neurofilament Light Chain)
    |
    TXA-127
    2years
    Phase 2 Study to Evaluate the Safety and Efficacy of Daily SC Injection of TXA127 in Post-ischemic Stroke Patients (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Constant Therapeutics LLC
    New P2 trial
    |
    BDNF (Brain Derived Neurotrophic Factor) • NEFL (Neurofilament Light Chain)
    |
    TXA-127
    5years
    Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=75, Terminated, Tarix Pharmaceuticals | Trial completion date: Mar 2022 --> Dec 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Dec 2020
    Clinical • Trial completion date • Trial termination • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    TXA-127
    5years
    USBTXA127CBT: TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (clinicaltrials.gov)
    P1, N=20, Terminated, Tarix Pharmaceuticals | Trial completion date: Mar 2022 --> Dec 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Dec 2020
    Clinical • Trial completion date • Trial termination • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    FLT3 mutation
    |
    TXA-127
    5years
    Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, Tarix Pharmaceuticals | Trial completion date: Sep 2020 --> Mar 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    TXA-127
    5years
    USBTXA127CBT: TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Tarix Pharmaceuticals | Trial completion date: Sep 2020 --> Mar 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    FLT3 mutation
    |
    TXA-127